Thu Jun 03 2021

A suPAR level below 4 ng/mL can be a useful discharge marker.

suPAR cut-offs <4, between 4-6 and >6 ng/mL can identify acute medical patients who have low, medium, or high risk of 30- and 90-day mortality.

In this new prospective observational study of acute medical patients, conducted at Mikkeli Hospital in Finland, suPAR was measured using the suPARnostic® Turbilatex assay on a Cobas c501 (Roche DiagnosticsLtd) analyzer. Previously suggested cut-offs of suPAR that may indicate low-medium and high risk of 30- and 90-day follow-up were tested.

The results show that suPAR provides significant prognostic patient value. Patients with a suPAR level below 4 ng/mL have a low risk of 30- and 90-day mortality (less than 1%), whereas 90-day mortality reached above 20% in patients with suPAR above 6 ng/mL. This high negative predictive value in patients with suPAR levels below 4 ng/mL can aid in the decision to discharge patients, in combination with other clinical findings.

Important results:

  • suPAR, independently of age, sex, and C-reactive protein levels, predicted 30- and 90-day mortality.
  • Among the 1747 acute medical patients, almost half had a suPAR level below 4 ng/mL, and the 30- and 90-day risk of mortality in these patients was below 1%.
  • Patients with suPAR above 6 ng/mL (1 in 4 patients) had high 90-day mortality of 20%.

Conclusion:

suPAR cut-offs of below 4, between 4-6, and above 6 ng/mL can identify acute medical patients who have a low, medium, or high risk of 30- and 90-day mortality. A suPAR level below 4 ng/mL can thus be useful as a discharge marker. The turbidimetric assay provides fast results that can improve decisions of discharge or admission of acute medical patients.

+800

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

suPAR is used in clinical routine in 38 hospitals

38 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling. This period covers October 1, 2021, until September 30, 2022.
Some hospital locations cannot be disclosed due to confidentiality.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates